

Genomic RNA from Influenza B Virus, B/Malaysia/2506/04

Catalog No. NR-10048

For research use only. Not for human use.

Contributor:

Alexander Klimov, Ph.D., Chief, Viral Surveillance and Diagnostic Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

Manufacturer:

NIH Biodefense and Emerging Infections Research Resources Repository

Product Description:

Genomic RNA was isolated from a preparation of pooled allantoic fluid from specific-pathogen free embryonated chicken eggs infected with influenza B virus, B/Malaysia/2506/04.

Influenza B/Malaysia/2506/04 was originally isolated on June 12, 2004 from a human nasal swab in Malaysia.¹ Influenza B/Malaysia/2506/04-like viruses were used as part of trivalent influenza vaccines worldwide from 2006-2008.²

NR-10048 has been qualified for PCR applications by amplification of an approximately 1080 nucleotide sequence. Recommended dilutions for successful RT-PCR amplification are indicated on the Certificate of Analysis for each lot.

Material Provided:

Each vial contains 100 µL of viral genomic RNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0) containing sodium azide. The viral genomic RNA is in a background of cellular nucleic acid and carrier RNA. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-10048 was packaged aseptically in screw-capped plastic cryovials. **The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. Note: The storage temperature indicated on the vial for Lot 58774797 is incorrect.** Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Genomic RNA from Influenza B Virus, B/Malaysia/2506/04, NR-10048."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Dr. Alexander Klimov, personal communication.
2. [WHO Recommendations for Influenza Vaccines](#)
3. Daum, L. T., et al. "Molecular Analysis of Isolates from Influenza B Outbreaks in the U.S. and Nepal, 2005." Arch. Virol. 151 (2006): 1863-1874. PubMed: 16736092.

ATCC® is a trademark of the American Type Culture Collection.

